PharmaJet has signed a Distribution Agreement with ATR, an affiliate of EVA Pharma, aimed at enhancing access to needle-free vaccinations in Egypt and the broader region. The agreement was finalized on October 30, 2025, during the CPHI meeting in Frankfurt. It includes arrangements for the distribution, technology transfer, and manufacturing of PharmaJet’s needle-free injection technology.
This collaboration seeks to improve the immunization process, supporting Egypt’s “1000 Golden Days” initiative designed to aid health and development during critical early childhood stages. The introduction of needle-free delivery methods is expected to reduce costs associated with polio vaccinations while increasing acceptance and coverage.
The partnership follows a Memo of Understanding established in July 2025 between PharmaJet, Egypt’s Unified Procurement Agency, and EVA Pharma, outlining plans for integrating this technology into public health programs. Both companies emphasize the importance of local manufacturing and innovation in expanding healthcare access.
Riad Armanious, CEO of EVA Pharma, stated, “This collaboration puts children first. We’re reimagining vaccination through local innovation that improves every child’s experience while empowering healthcare professionals.” Paul LaBarre, Senior Vice President of Business Development for PharmaJet, added that this partnership marks a significant advancement for needle-free vaccination in the Middle East and Northern Africa.
The primary source was Business Wire.
